+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 50Years - 99Years
MALE
Healthy Volunteers
ID05148156

Evaluating Urolift to Reduce Urinary Side Effects from Radiation Therapy in Men with BPH and Prostate Cancer

Led by Northwell Health · Updated on 2026-09-29

20

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate whether Urolift, a minimally invasive procedure, can reduce urinary side effects caused by stereotactic body radiation therapy SBRT in male patients with benign prostatic hyperplasia BPH and prostate cancer. These side effects include increased urinary frequency, pain during urination, and nighttime urination. Urolift is already a standard treatment for BPH, designed to keep the prostatic urethra open by placing a stainless-steel implant. Participants will receive a one-time Urolift procedure before starting SBRT for prostate cancer. Urolift involves placing end pieces on both sides of the prostatic urethra to maintain an open urinary channel. The study involves only one group and includes one year of follow-up after treatment to assess urinary symptoms and quality of life. During the study, participants will complete questionnaires to measure urinary symptoms and quality of life over an average of one year. Researchers will track changes in urinary symptom scores, sexual function, pain levels, overactive bladder symptoms, and overall health quality. Medication use for urinary symptoms will also be monitored. The study is led by Northwell Health and lasts until March 2028.

CONDITIONS

Brief Title

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

Research Team

J

Jennifer Polo, CCRC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here